Lido Advisors LLC Sells 89,689 Shares of Astrazeneca Plc $AZN

Lido Advisors LLC cut its stake in Astrazeneca Plc (NYSE:AZN) by 68.1% in the 1st quarter, Holdings Channel reports. The fund owned 42,073 shares of the company’s stock after selling 89,689 shares during the quarter. Lido Advisors LLC’s holdings in Astrazeneca were worth $8,298,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. IHT Wealth Management LLC raised its position in Astrazeneca by 0.3% during the fourth quarter. IHT Wealth Management LLC now owns 17,527 shares of the company’s stock valued at $3,076,000 after purchasing an additional 54 shares in the last quarter. Visionary Wealth Advisors boosted its holdings in shares of Astrazeneca by 1.5% in the 4th quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock worth $737,000 after purchasing an additional 60 shares in the last quarter. Vista Investment Management boosted its holdings in shares of Astrazeneca by 0.3% in the 4th quarter. Vista Investment Management now owns 21,215 shares of the company’s stock worth $3,723,000 after purchasing an additional 60 shares in the last quarter. Kestra Investment Management LLC increased its position in shares of Astrazeneca by 1.9% during the 4th quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock valued at $595,000 after purchasing an additional 63 shares during the last quarter. Finally, Luken Investment Analytics LLC increased its position in shares of Astrazeneca by 4.3% during the 4th quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock valued at $274,000 after purchasing an additional 64 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Up 0.2%

Shares of NYSE AZN opened at $168.68 on Friday. The firm’s fifty day moving average is $180.55 and its 200 day moving average is $187.97. Astrazeneca Plc has a 52 week low of $142.98 and a 52 week high of $212.71. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The company has a market cap of $261.61 billion, a price-to-earnings ratio of 25.33, a PEG ratio of 1.37 and a beta of 0.24.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. On average, equities research analysts expect that Astrazeneca Plc will post 10.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on AZN shares. Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Wall Street Zen raised Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. UBS Group reiterated a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Bank of America reissued a “buy” rating on shares of Astrazeneca in a research note on Wednesday, July 1st. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Astrazeneca currently has an average rating of “Moderate Buy” and an average target price of $211.00.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.